https://phaidra.vetmeduni.ac.at/o:2951 JAK-Inhibitors - A Story of Success and Adverse Events Wlassits, Rebekka Rebekka Wlassits Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie Müller, Mathias Mathias Müller 0000-0002-7879-3552 University of Veterinary Medicine Vienna Fenzl, Karl H. Karl H. Fenzl Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie Lamprecht, Thomas Thomas Lamprecht Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie Erlacher, Ludwig Ludwig Erlacher Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie Dove Medical Press Ltd text eng Rheumatoid arthritis (RA) is a systemic, chronic, immune-mediated inflammatory condition. Treatments options encompass conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic disease-modifying antirheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors (TNFis) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) including Janus Kinase inhibitors (JAKinibs). Orally administered JAKinibs have demonstrated comparable or, in specific cases, superior efficacy compared to bDMARDs in inflammatory conditions. However, the escalating clinical utilization has been accompanied by the emergence of serious adverse effects, including major adverse cardiac events (MACE), malignancies and venous thrombotic episodes (VTE), leading to regulatory restrictions imposed by health authorities in both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Protein-Tyrosine Kinase; Rheumatoid-Arthritis; Interferon-Alpha/Beta; Cardiovascular Events; Psoriatic-Arthritis; Cancer-Risk; Tofacitinib; Metaanalysis; Mortality; Inflammation http://creativecommons.org/licenses/by-nc/4.0/ https://phaidra.vetmeduni.ac.at/api/object/o:2951/download 10.2147/OARRR.S436637 https://phaidra.vetmeduni.ac.at/o:605 application/pdf Open Access Rheumatology - Research and Reviews 16, 43-53 (2024) Open Access Rheumatology - Research and Reviews 16 43 53 430.48 kB 2024